IDEXX Laboratories, Inc. $IDXX Shares Purchased by Portland Global Advisors LLC

Portland Global Advisors LLC lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 323.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,147 shares of the company’s stock after acquiring an additional 6,224 shares during the quarter. Portland Global Advisors LLC’s holdings in IDEXX Laboratories were worth $5,512,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in IDXX. Elyxium Wealth LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $3,666,459,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of IDEXX Laboratories by 63,503.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after acquiring an additional 1,442,174 shares during the last quarter. Norges Bank acquired a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $332,265,000. JPMorgan Chase & Co. lifted its holdings in shares of IDEXX Laboratories by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after acquiring an additional 326,348 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI acquired a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $143,730,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.79% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. UBS Group decreased their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. BTIG Research reduced their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Piper Sandler reduced their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Finally, Citigroup began coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $563.53 on Friday. The firm has a market cap of $44.45 billion, a PE ratio of 41.50, a price-to-earnings-growth ratio of 3.27 and a beta of 1.58. IDEXX Laboratories, Inc. has a 52-week low of $504.56 and a 52-week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company’s 50 day moving average is $564.58 and its two-hundred day moving average is $637.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.